Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Coherus Oncology, Inc. - Common Stock (NQ:CHRS)

1.560 +0.110 (+7.59%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,535,257
Open 1.440
Bid (Size) 1.410 (300)
Ask (Size) 1.550 (200)
Prev. Close 1.450
Today's Range 1.425 - 1.600
52wk Range 0.7330 - 2.616
Shares Outstanding 116,236,018
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Coherus and Zumutor Biologics Announce Clinical Collaboration to Evaluate ZM008 in Combination with LOQTORZI® (toripalimab-tpzi)
– First patient dosed in a Phase 1 study evaluating ZM008, an anti-LLT1 mAb, in combination with LOQTORZI, a next-generation PD-1 inhibitor – 
From Coherus Oncology, Inc.
Via GlobeNewswire
News headline image
Solid Tumor Treatment Race Heats Up as Multi-Billion-Dollar Oncology Market Enters High-Growth Phase
EQNX::TICKER_START (NASDAQ:GTBP),(NASDAQ:ARTV),(NASDAQ:FATE),(NASDAQ:IBRX),(NASDAQ:CHRS) EQNX::TICKER_END 
Via FinancialNewsMedia

Performance

YTD
+13.9%
+13.9%
1 Month
+7.6%
+7.6%
3 Month
-6.6%
-6.6%
6 Month
+8.3%
+8.3%
1 Year
+109.1%
+109.1%

More News

Read More
News headline image
Coherus Oncology Q1 Earnings Call Highlights ↗
Via MarketBeat
Topics Earnings
Coherus Oncology (NASDAQ:CHRS) Q1 Revenue Misses Estimates Despite LOQTORZI Growth ↗
Via Chartmill
Coherus Oncology Inc (NASDAQ:CHRS) Reports Mixed Q4 2025 Results as LOQTORZI Sales Grow ↗
Via Chartmill
News headline image
CHRS Q1 2026 Earnings Transcript ↗
Via The Motley Fool
News headline image
Coherus Oncology Reports First Quarter 2026 Financial Results and Provides Business Update
From Coherus Oncology, Inc.
Via GlobeNewswire
News headline image
Coherus Oncology to Report First Quarter 2026 Financial Results on May 11, 2026
From Coherus Oncology, Inc.
Via GlobeNewswire
News headline image
Coherus Oncology Reports Full Year and Fourth Quarter 2025 Financial Results and Provides Business Update
From Coherus Oncology, Inc.
Via GlobeNewswire
News headline image
Coherus Oncology to Report Full Year and Fourth Quarter 2025 Financial Results on March 9, 2026
From Coherus Oncology, Inc.
Via GlobeNewswire
News headline image
Coherus Oncology to Participate in Upcoming Investor Conferences
From Coherus Oncology, Inc.
Via GlobeNewswire
News headline image
Coherus Oncology, Inc. Announces Closing of Public Offering of Common Stock
From Coherus Oncology, Inc.
Via GlobeNewswire
What's going on in today's pre-market session ↗
Via Chartmill
News headline image
Coherus Oncology, Inc. Announces Pricing of Public Offering of Common Stock
From Coherus Oncology, Inc.
Via GlobeNewswire
News headline image
Coherus Oncology, Inc. Announces Proposed Public Offering of Common Stock
From Coherus Oncology, Inc.
Via GlobeNewswire
These stocks have an unusual volume in today's session ↗
Via Chartmill
What's going on in today's session ↗
Via Chartmill
Which stocks are moving on Friday? ↗
Via Chartmill
The market is filled with gapping stocks in Friday's session. ↗
Via Chartmill
Wondering what's happening in today's after-hours session? ↗
Via Chartmill
News headline image
The $225B Precision Sprint: How Big Pharma is Beating the $170B Patent Cliff
From Equity Insider
Via GlobeNewswire
News headline image
Coherus Management to Present at the 44th Annual J.P. Morgan Healthcare Conference
From Coherus Oncology, Inc.
Via GlobeNewswire
News headline image
Coherus Oncology Announces Publication in Molecular Cancer Therapeutics Highlighting the Strong Pharmacology of Investigational CCR8 Antibody Tagmokitug (CHS-114)
From Coherus Oncology, Inc.
Via GlobeNewswire
News headline image
Coherus Announces Six-Year JUPITER-02 Follow-up Results Showing LOQTORZI® plus Chemotherapy Nearly Doubles Median Overall Survival in Nasopharyngeal Carcinoma
From Coherus Oncology, Inc.
Via GlobeNewswire
News headline image
Coherus Oncology Presents at SITC Clinical Multiomic Biomarker Data for CHS-114, a Highly Selective anti-CCR8 Cytolytic Antibody
From Coherus Oncology, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Coherus Oncology, Inc. - Common Stock publicly traded?
Yes, Coherus Oncology, Inc. - Common Stock is publicly traded.
What exchange does Coherus Oncology, Inc. - Common Stock trade on?
Coherus Oncology, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Coherus Oncology, Inc. - Common Stock?
The ticker symbol for Coherus Oncology, Inc. - Common Stock is CHRS on the Nasdaq Stock Market
What is the current price of Coherus Oncology, Inc. - Common Stock?
The current price of Coherus Oncology, Inc. - Common Stock is 1.560
When was Coherus Oncology, Inc. - Common Stock last traded?
The last trade of Coherus Oncology, Inc. - Common Stock was at 07/06/26 04:00 PM ET
What is the market capitalization of Coherus Oncology, Inc. - Common Stock?
The market capitalization of Coherus Oncology, Inc. - Common Stock is 181.33M
How many shares of Coherus Oncology, Inc. - Common Stock are outstanding?
Coherus Oncology, Inc. - Common Stock has 181M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.